Why you should stop scrolling in the bathroom and the unsavory truth about your phone.

Published Date: 26 Apr 2023

More than 90% of people in the world own or use a mobile phone, and many of us couldn't live without them. We carry them everywhere we go, use them in bed and the bathroom, and for many people, they are the first thing they see in the morning.

Read Full News

Latest News

Michigan Reports 9,253 Cyclosporiasis Cases as Infection Outbreak Expands

Michigan health officials reported 9,253 cases of cyclosporiasis on Monday, an increase of 1,077 cases since their last update on Friday, as ⁠the intestinal infection...

Uganda Declares End to Latest Ebola Outbreak

Uganda's health minister declared the country Ebola-free following the nation's latest ⁠outbreak of the viral hemorrhagic disease that infected 20 people and killed two of them.

A Day in the Life Of Congo's Overstretched Ebola Surveillance Teams

On a good day, there are only four cars available to ferry surveillance teams round the city of Bunia, the epicentre of an Ebola outbreak surging through the Democratic...

Low-Dose CT and PCR Fail to Cut Antibiotic Use in Pneumonia

In hospitalized adults with community-acquired pneumonia, low-dose chest CT does not lower broad-spectrum antibiotic use, whereas multiplex polymerase chain reaction may provide a modest benefit.

US FDA Widens Investigation Into Cyclosporiasis Cases to Four More States

The U.S. FDA and the CDC are widening their investigation into a cyclosporiasis outbreak linked to shredded iceberg lettuce from central Mexico after identifying ⁠cases in...

Nearly 3,000 Confirmed Infected With Ebola in Congo After Data Review

The number of people confirmed infected with Ebola in the Democratic ⁠Republic of Congo was heading towards 3,000 on Friday after officials reviewed data ⁠in two of the...

Todays Updates

Trial Challenges Indefinite Maintenance for Multiple Myeloma

A randomized trial questions whether patients with standard-risk multiple myeloma need indefinite lenalidomide maintenance.

Blinatumomab May Improve Survival in High-Risk Adult B-ALL

A phase 2 trial evaluates the benefit of adding blinatumomab to consolidation therapy in adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Todays Updates

Trial Challenges Indefinite Maintenance for Multiple Myeloma

A randomized trial questions whether patients with standard-risk multiple myeloma need indefinite lenalidomide maintenance.

Blinatumomab May Improve Survival in High-Risk Adult B-ALL

A phase 2 trial evaluates the benefit of adding blinatumomab to consolidation therapy in adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Latest News

Michigan health officials reported 9,253 cases of cyclosporiasis on Monday, an increase of 1,077 cases since their last update on Friday, as ⁠the intestinal infection...

Uganda's health minister declared the country Ebola-free following the nation's latest ⁠outbreak of the viral hemorrhagic disease that infected 20 people and killed two of them.

On a good day, there are only four cars available to ferry surveillance teams round the city of Bunia, the epicentre of an Ebola outbreak surging through the Democratic...

In hospitalized adults with community-acquired pneumonia, low-dose chest CT does not lower broad-spectrum antibiotic use, whereas multiplex polymerase chain reaction may provide a modest benefit.

The U.S. FDA and the CDC are widening their investigation into a cyclosporiasis outbreak linked to shredded iceberg lettuce from central Mexico after identifying ⁠cases in...

The number of people confirmed infected with Ebola in the Democratic ⁠Republic of Congo was heading towards 3,000 on Friday after officials reviewed data ⁠in two of the...

News All Time

Gilead, Merck Weekly HIV Pill Keeps Virus Suppressed in Late-stage Trials

Gilead Sciences and Merck said on Tuesday their experimental once-weekly HIV pill kept the virus suppressed in ⁠two late-stage trials, supporting regulatory filings for what...

Fewer Children Got US-backed HIV Treatment After Aid Cuts, Study Finds

(Refiles to add missing byline)

Cyclosporiasis Surge: A Clinician's Quick Guide

With a 34-state Cyclospora outbreak driving GI visits, Dr Levy breaks down diagnosis, testing pitfalls, and treatment clinicians need to know.

US FDA Says False-positive Lettuce Test Doesn't Change Taylor Farms Cyclospora Probe

The U.S. Food and Drug Administration on Monday defended publicizing a lettuce sample later found to be ⁠a false positive for cyclospora, saying the reversal does not...

What Has Made the Cyclospora Behind the US Outbreak So Challenging to Trace?

Cyclospora, the parasite behind thousands of suspected U.S. cases of a foodborne illness, has a long incubation period, and samples cannot be cultured in labs, making it...

Japanese Drugmaker Takeda's Qdenga Becomes First Dengue Vaccine Approved in India

Takeda Pharmaceutical's dengue vaccine Qdenga has been approved by India's drug regulator, making it the first such vaccine to be cleared in the country, the Japanese...

India's Serum Institute Partners With Gates MRI to Make Experimental TB Vaccine

(Corrects to fix typo in the headline)

New Zealand Confirms First H5N1 Bird Flu Case in Native Bird

New Zealand detected on Friday the first infection of a native bird ⁠by the deadly H5N1 bird flu, days after confirming a migratory seabird had tested ⁠positive in the...

Congo Begins Trial Of Gilead's Experimental Antiviral for Ebola Bundibugyo

Researchers in the Democratic Republic of Congo said on Tuesday they have started enrolling participants in ⁠a trial testing Gilead Sciences' experimental antiviral...

Gen Z Fitness Trend: Are Group Workouts Better?

Community fitness may improve exercise adherence and mental well-being through social support, although evidence shows that it offers few additional physical benefits.

What to Know About the US Outbreak Of Cyclosporiasis

The U.S. Centers for Disease Control and Prevention said on Tuesday it had confirmed 1,645 cases of an intestinal infection from the cyclospora parasite that causes...

Oxford Begins First Human Trial Of Bundibugyo Ebola Vaccine

The University of Oxford has launched the first human trial of a vaccine against Bundibugyo ebolavirus, seeking to accelerate ⁠efforts to combat an outbreak spreading in the...

Two- vs Three-Drug Combo for HIV Infection: No Clear Winner

Among treatment-naive adults living with HIV, CD4 to CD8 ratios do not differ significantly between those on dolutegravir plus lamivudine and those on integrase inhibitor-based three-drug regimens.

Nintedanib Shows No Benefit Over Placebo in Post-COVID ILD

Among patients with post-COVID interstitial lung disease, nintedanib does not provide significant benefit over placebo.

Congo Ebola Response Workers Protest Over Pay

Ebola response workers in northeastern Democratic Republic of Congo staged protests outside three treatment centres on Thursday, saying ⁠they had not been paid all they were...

Ebola Outbreak in Congo Still Spreading, WHO Says

The Ebola outbreak in Congo has not yet stabilised and is still expanding as population ⁠movement fuels transmission, a World Health Organization official said on...

Recommended News For You

For relapsed or resistant DLBCL, odronextamab produced positive results.

Alkem introduces cetuximab under the trade name Cetuxa in India.

In cases of locally advanced, potentially curable pancreatic cancer, a combination of drugs enhances the results of radiation therapy.

The pathology of incurable cancers can be predicted thanks to research.

AI is equally capable of reading breast cancer scans as human radiologists.

Radioligand Therapy Set to Transform Oncology Care

The self-sacrificing nature of breast cancer cells has been identified as a possible reason for relapse.

Recommended Articles For You

Clinical Methods in Hematology and Quality Improvement 

Gene-Regulated Hematopoietic Restoration Technologies 

Metabolic Competition Within the Tumor Ecosystem: Mechanisms, Clinical Relevance, and Therapeutic Advances 

Advanced Approaches in Oncology and Patient Outcomes 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

2.

Quads, Frailty, and the Future: Evolving Frontline Strategies in Multiple Myeloma

3.

VP Nominee Medical Records Breached; Queen Elizabeth's Cancer; Galaxy Gas Whippets

4.

New study reveals racial disparities in breast cancer diagnosis and outcomes in Canada

5.

Reduced Suicide Rates in Cancer Patients; Enhanced Circadian Rhythm; HIV Vaccine for Cancer Patients?

1.

Unlocking the Power of Cryoprecipitate: A Comprehensive Guide

2.

Comprehensive Standards in Oncology for Modern Medicine

3.

Everything You Need to Know About Leiomyomas: A Comprehensive Guide 

4.

Artificial Intelligence for Early Cancer Detection Leveraging Multi-Omics: A Comprehensive Review

5.

Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII

3.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation

4.

First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials

5.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot